domingo, 2 de diciembre de 2018

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL | NEJM

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL | NEJM

ASH in 30 Seconds

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

  • Jennifer A. Woyach, M.D., 
  • Amy S. Ruppert, Ph.D., 
  • Nyla A. Heerema, Ph.D., 
  • Weiqiang Zhao, M.D., 
  • Allison M. Booth, M.S., 
  • Wei Ding, M.B., B.S., Ph.D., 
  • Nancy L. Bartlett, M.D., 
  • Danielle M. Brander, M.D., 
  • Paul M. Barr, M.D., 
  • Kerry A. Rogers, M.D., 
  • Sameer A. Parikh, M.B., B.S., 
  • Steven Coutre, M.D., 

No hay comentarios: